© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 13, 1131-1137,
July 7, 1999
© 1999 Oxford University Press
Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins
Affiliations of authors: E. Weiderpass, C. Magnusson, N. Correia, I. Persson, Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden; H.-O. Adami, Department of Medical Epidemiology, Karolinska Institutet, and Department of Epidemiology and Harvard Center for Cancer Prevention, Harvard University, Boston, MA; J. A. Baron, Dartmouth Medical School, Hanover, NH; R. Bergström, Department of Medical Epidemiology, Karolinska Institutet, and Department of Statistics, Uppsala University, Sweden; A. Lindgren, Department of Pathology, Falun Hospital, Sweden.
Correspondence to: Elisabete Weiderpass, M.D., M.Sc., Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden (e-mail: Elisabete.Weiderpass{at}mep.ki.se).
BACKGROUND: Unopposed estrogen replacement therapy (i.e., estrogen without progestins) increases the risk of endometrial cancer. In this study, we examined the endometrial cancer risk associated with combined estrogen-progestin regimens currently in use, since the safety profiles of these regimens have not been clearly defined. METHODS: We conducted a nationwide population-based, case-control study in Sweden of postmenopausal women aged 50-74 years. We collected information on use of hormone replacement from 709 case patients with incident endometrial cancer and from 3368 control subjects. We used unconditional logistic regression to calculate odds ratios (ORs) as estimates of relative risks. All individual comparisons were made with women who never used the respective hormone replacement regimens. RESULTS: Treatment with estrogens alone was associated with a marked duration- and dose-dependent increase in the relative risk of endometrial cancer. Five or more years of treatment had an OR of 6.2 for estradiol (95% confidence interval [CI] = 3.1-12.6) and of 6.6 for conjugated estrogens (95% CI = 3.6-12.0). Following combined estrogen-progestin use, the association was considerably weaker than that for estrogen alone; the OR was 1.6 (95% CI = 1.1-2.4) after 5 or more years of use. This increase in risk was confined to women with cyclic use of progestins, i.e., fewer than 16 days per cycle (most commonly 10 days per cycle [OR = 2.9; 95% CI = 1.8-4.6 for 5 or more years of use]), whereas continuous progestin use along with estrogens was associated with a reduced risk (OR = 0.2; 95% CI = 0.1-0.8 for 5 or more years of use). CONCLUSION: The risk of developing endometrial cancer is increased after long-term use of estrogens without progestins and with cyclically added progestins. Continuously added progestins may be needed to minimize the endometrial cancer risk associated with estrogen replacement therapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Jensen, H. Sharif, and S. K. Kjaer Use of Fertility Drugs and Risk of Uterine Cancer: Results From a Large Danish Population-based Cohort Study Am. J. Epidemiol., December 1, 2009; 170(11): 1408 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Engman, L. Skoog, G. Soderqvist, and K. Gemzell-Danielsson The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology Hum. Reprod., September 1, 2008; 23(9): 2072 - 2079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Akesson, B. Julin, and A. Wolk Long-term Dietary Cadmium Intake and Postmenopausal Endometrial Cancer Incidence: A Population-Based Prospective Cohort Study Cancer Res., August 1, 2008; 68(15): 6435 - 6441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rees and S. Hope Use of unopposed systemic estrogen therapy in non-hysterectomized women: a population-based study in the UK Menopause Int, June 1, 2008; 14(2): 83 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Viswanathan, D. Feskanich, E. S. Schernhammer, and S. E. Hankinson Aspirin, NSAID, and Acetaminophen Use and the Risk of Endometrial Cancer Cancer Res., April 1, 2008; 68(7): 2507 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Deming, W. Zheng, W.-H. Xu, Q. Cai, Z. Ruan, Y.-B. Xiang, and X.-O. Shu UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Einarsdottir, K. Humphreys, C. Bonnard, Y. Li, Y. Li, K. S. Chia, E. T. Liu, P. Hall, J. Liu, and S. Wedren Effect of ATM, CHEK2 and ERBB2 TAGSNPs and haplotypes on endometrial cancer risk Hum. Mol. Genet., January 15, 2007; 16(2): 154 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Strom, R. Schinnar, A. L. Weber, G. Bunin, J. A. Berlin, M. Baumgarten, A. DeMichele, S. C. Rubin, M. Berlin, A. B. Troxel, et al. Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer Am. J. Epidemiol., October 15, 2006; 164(8): 775 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Wood, S. E. Appt, T. B. Clarkson, A. A. Franke, C. J. Lees, D. R. Doerge, and J. M. Cline Effects of High-Dose Soy Isoflavones and Equol on Reproductive Tissues in Female Cynomolgus Monkeys Biol Reprod, September 1, 2006; 75(3): 477 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Weiss, B. S. Saltzman, J. A. Doherty, L. F. Voigt, C. Chen, S. A. A. Beresford, D. A. Hill, and N. S. Weiss Risk Factors for the Incidence of Endometrial Cancer according to the Aggressiveness of Disease Am. J. Epidemiol., July 1, 2006; 164(1): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss Inflammation and Endometrial Cancer: A Hypothesis Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2840 - 2847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.R.E. Hampton, M.C.P. Rees, D.G. Lowe, I. Rauramo, D. Barlow, and J. Guillebaud Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: a successful regimen for HRT in perimenopausal women Hum. Reprod., September 1, 2005; 20(9): 2653 - 2660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Lacey Jr., L. A. Brinton, J. H. Lubin, M. E. Sherman, A. Schatzkin, and C. Schairer Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1724 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Rylander-Rudqvist, S. Wedren, G. Jonasdottir, S. Ahlberg, E. Weiderpass, I. Persson, and M. Ingelman-Sundberg Cytochrome P450 1B1 Gene Polymorphisms and Postmenopausal Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1515 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Anderson, H. L. Judd, A. M. Kaunitz, D. H. Barad, S. A. A. Beresford, M. Pettinger, J. Liu, S. G. McNeeley, and A. M. Lopez Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures: The Women's Health Initiative Randomized Trial JAMA, October 1, 2003; 290(13): 1739 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rymer, R. Wilson, and K. Ballard Making decisions about hormone replacement therapy BMJ, February 8, 2003; 326(7384): 322 - 326. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Barlow Time to reflect on the Women's Health Initiative (WHI) Study Hum. Reprod., January 1, 2003; 18(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
R. Kaaks, A. Lukanova, and M. S. Kurzer Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1531 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, and I. R. Persson Risk Factors for Invasive Epithelial Ovarian Cancer: Results from a Swedish Case-Control Study Am. J. Epidemiol., August 15, 2002; 156(4): 363 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F Archer Continuous combined hormone replacement therapy and endometrial hyperplasia BMJ, August 3, 2002; 325(7358): 231 - 232. [Full Text] [PDF]
|
|
|
|
|
|
M. Wells, D. W Sturdee, D. H Barlow, L. G Ulrich, K. O'Brien, M. J Campbell, M. P Vessey, and A. J Bragg Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study BMJ, August 3, 2002; 325(7358): 239 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Wickerham, B. Fisher, N. Wolmark, J. Bryant, J. Costantino, L. Bernstein, and C. D. Runowicz Association of Tamoxifen and Uterine Sarcoma J. Clin. Oncol., June 1, 2002; 20(11): 2758 - 2760. [Full Text] [PDF]
|
|
|
|
|
|
M. Wahab, J. Thompson, M. Whitehead, and F. Al-Azzawi The effect of a change in the dose of trimegestone on the pattern of bleeding in estrogen-treated post-menopausal women: 6 month extension of a dose-ranging study Hum. Reprod., May 1, 2002; 17(5): 1386 - 1390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, E. Weiderpass, and I. R. Persson Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women J Natl Cancer Inst, April 3, 2002; 94(7): 497 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Hale, C. L. Hughes, and J. M. Cline Endometrial Cancer: Hormonal Factors, the Perimenopausal ""Window of Risk,"" and Isoflavones J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 3 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Terry, A. Wolk, H. Vainio, and E. Weiderpass Fatty Fish Consumption Lowers the Risk of Endometrial Cancer: A Nationwide Case-Control Study in Sweden Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 143 - 145. [Abstract] [Full Text]
|
|
|
|
 |
|
 K M Feeley and M Wells Hormone replacement therapy and the endometrium J. Clin. Pathol., June 1, 2001; 54(6): 435 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Al-Azzawi The menopause and its treatment in perspective Postgrad. Med. J., May 1, 2001; 77(907): 292 - 304. [Full Text]
|
|
|
|
 |
|
 R. A. Smith, A. C. von Eschenbach, R. Wender, B. Levin, T. Byers, D. Rothenberger, D. Brooks, W. Creasman, C. Cohen, C. Runowicz, et al. American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001--Testing for Early Lung Cancer Detection CA Cancer J Clin, January 1, 2001; 51(1): 38 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Foca, G.E. Rice, M.A. Quinn, and E.K. Moses Identification and partial characterization of differentially expressed mRNAs in normal human endometria and endometrial carcinomas by differential display RT-PCR Mol. Hum. Reprod., August 1, 2000; 6(8): 712 - 718. [Abstract] [Full Text] [PDF]
|
|